Our previous research showed that ERK1/2 activation in cancer cells promotes inflammatory osteolysis in bone.14,15 In the present study, we found that ERK1/2 is highly activated in human osteolytic cancer cell lines, but ERK1/2 is less activated in human osteoblastic cancer lines. This evidence concerns the gene MAPK3 and cancer.